Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to increased intracellular sodium. This change reduces calcium extrusion, raising intracellular calcium levels, which strengthens heart contractions and enhances vagal tone, thereby slowing conduction through the atrioventricular node.

The appropriate dose of Lanoxin is determined individually by the prescribing clinician based on factors such as the patient’s age, kidney function, electrolyte status, and serum digoxin concentration. Dosage adjustments are made to achieve therapeutic levels while minimizing toxicity.

Lanoxin is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; a decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Lanoxin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Unlike beta‑blockers or ACE inhibitors that modify neurohormonal pathways, digoxin provides a direct positive inotropic effect and rate control. It is often used as an adjunct when symptoms persist despite standard therapy, offering a unique mechanism that can improve exercise tolerance in selected patients.

Lanoxin tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Lanoxin is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the individualized dosing regimen established by the treating clinician.

The most critical concerns are digoxin toxicity, which can manifest as life‑threatening cardiac arrhythmias, severe bradycardia, or heart block. Electrolyte imbalances, especially low potassium or magnesium, increase this risk, making regular monitoring essential.

Lanoxin is contraindicated in patients with ventricular fibrillation, known hypersensitivity to digoxin, or uncontrolled ventricular arrhythmias. Caution is also advised for individuals with severe renal impairment, significant electrolyte disturbances, or those taking interacting medications without close supervision.